NCT01773785 2021-10-13
Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
Spectrum Pharmaceuticals, Inc
Columbia University
Korean South West Oncology Group
ARCAGY/ GINECO GROUP